Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI - ...

YCT-529 inhibits retinoic acid receptor alpha to suppress sperm production reversibly. Currently in Phase 1b/2a trials, the compound has shown promise in preclinical models and aims to expand ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...

CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer ...